455 results about "Tissue Adhesion" patented technology

Molecular cross-linked gels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such molecular gels may be applied to target sites in a patient's body by extruding the gel through an orifice at the target site. Alternatively, the gels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

The invention relates to a modified starch material for biocompatible hemostasis, biocompatible anti-adhesion, tissue healing promotion, absorbable surgery sealing and tissue adhesion. The invention applies biocompatible modified starch to animal tissues, wherein the modified starch material has the molecular weight of more than 15,000 daltons, and the particle diameter of between 1 and 1,000 mu m. The modified starch hemostatic material has stypticity, reduces hemorrhage, blood oozing and tissue fluid oozing of wounds, maintains relative moistening or drying of wound surfaces or the wounds, inhibits bacterium growth and inflammation reaction, and contributes to locally diminish inflammation of the wounds and relieve pain of patients. Moreover, the modified starch material can wash local parts after operation is over and remove redundant modified starch which does not participate in hemostasis, and can easily remove haemostatic under the condition of debridement treatment after self-help and first-aid treatment of war wounds; and hemostatic materials with a small amount of modified starch can be absorbed by the body, so that the pain of tearing of gauzes and bandages on people is avoided.

Oral treatment devices include a barrier layer and an oral treatment composition, and optionally an auxiliary adhesive composition, that acts as an endoskeleton so as to at least partially contribute to maintaining the barrier layer in the shape of a dental tray, or in a tray-like configuration, prior to use. The barrier layer protects the oral treatment and/or adhesive composition from saliva or moisture during use. The treatment and/or auxiliary adhesive compositions can have a consistency ranging from a sticky, viscous gel or a solid. They preferably include a tissue adhesion agent comprising a hydrophilic polymer.

The present invention is directed to a method in which a supercritical fluid that comprises a carrier fluid and a biologically active agent is brought into contact with medical article that comprises a nanoporous surface region. A variety of medical articles may be used in the practice of the present invention, including implantable or insertable medical devices such as bone plates, joint prostheses, vascular grafts, stent grafts, stents, catheters, guide wires, balloons, filters, vascular patches, shunts, and coils, among others. The nanoporous surface region may be, for example, metallic, ceramic, or polymeric in nature. Examples of biologically active agents include antirestenotic agents and agents that promote tissue adhesion, among others. Carbon dioxide is one of many carrier fluids that may be employed.

A surgical drain device includes a matrix of biodegradable polymer material and a plurality of drain tubes attached to the matrix. The device is implanted within a surgical wound to treat the presence of seromas, for example, and is used to promote drainage, tissue adhesion, and wound closure. The drain tubes converge into a common collection tube that leads wound fluid outside the body under gravity feed or negative pressure applied to the collection tube. The matrix contains an array of apertures that allow tissue contact across the device. A preferred embodiment comprises a tissue anchoring system including anchor elements such as hooks or barbs. The device can be used with a negative pressure system to further improve the drainage band can also be used with a wound dressing. The device and systems containing the device are particularly useful to promote the healing of surgical wounds from abdominal surgery.

Dental bleaching compositions include a dental bleaching agent, a generally linear high molecular weight (i.e., greater than about 500,000) polyvinyl pyrrolidone (PVP) and/or polyethylene oxide (PEO) tissue adhesion agent included in amount that imparts a high level of adhesiveness, a rheology-modifying agent such as fumed silica or fumed alumina that reduces or eliminates stringiness otherwise caused by the high molecular weight PVP and/or PEO, and a solvent or carrier. Dental bleaching compositions may include carboxypolymethylene instead of or in addition to PVP and/or PEO, wherein the fumed silica or fumed alumina increases long-term rheological stability even in the presence of a high concentration of dental bleaching agent. Dental treatment devices including a barrier layer and a quantity of the dental bleaching composition positioned adjacent to the barrier layer.

The invention relates to a medical wound surface hemostatic and wound healing agent, which is characterized in that the invention consists of two parts of water solution, one part is the oxidative polysaccharide water solution containing dialdehyde, and the other part is the water-soluable chitosan water solution. The medical wound surface hemostatic and wound healing agent can be applied in the preparation of drugs or medical devices for wound surface sealing and wound surface hemostasis, and the invention can also be applied in the preparation of drugs or medical devices for the promotion of wound surface healing and the prevention of postoperative tissue adhesion. The medical wound surface hemostatic and wound healing agent of the invention has significant effects on wound surface sealing, hemostasis, promotion of wound surface healing, prevention of postoperative tissue adhesion and other aspects, at the same time, the biocompatibility is good, which can not cause the tissue immune response, and the polysaccharides can not generate side effects on organisms after the in vivo degradation, so the safety is good.

This invention is related to an adhesive composition which may be used to bond or seal tissue in vivo. The adhesive composition is readily formed from a two component mixture which includes a first part of a protein, preferably a serum albumin protein, in an aqueous buffer having a pH in the range of about 8.0-11.0 and a second part of a water-compatible or water-soluble bifunctional crosslinking agent. When the two parts of the mixture are combined, the mixture is initially a liquid which cures in vivo on the surface of tissue in less than about one minute to give a strong, flexible, pliant substantive composition which bonds to the tissue and is absorbed in about four to sixty days. The adhesive composition may be used either to bond tissue, to seal tissue or to prevent tissue adhesions caused by surgery.

The invention relates to a preparation method of a biological mimetic and structural bionic tissue adhesive in order to overcome disadvantages of present technological technologies for preparing mussel mucoprotein bionic biological tissue adhesives and improve the viscosity, the biocompatibility and the structural bionic property of a material. The preparation method comprises the following steps: grafting a natural polymer material with dopamine or other catechol group-containing derivatives through an amidation reaction by adopting DMTMM as a carboxyl group activator; and further modifying the grafted natural polymer material with lysine or polylysine by adopting the same technology to obtain the novel biological mimetic and structural bionic tissue adhesive containing dopamine analog and polylysine analog. The tissue adhesive plays a full role in tissue adhesion in wet and physiologic environment, has good tissue adherence and high biological safety, and can be slowly degraded in the tissue healing process until complete degradation. The preparation method of the biological adhesive has the advantages of simplicity, mild reaction conditions, increase of the reaction efficiency, improvement of the operability of the enterprise production process, and facilitation of amplified production of enterprises.

A composition, method, and use of microporous particles such as polysaccharide hemostat particle gels activates platelet rich plasma (PRP) or other platelet-containing substances. The composition may contain microporous polysaccharaide hemostats (MPH) mixed with platelet-rich plasma, platelet-poor plasma, blood, or the like. The method may contain mixing the MPH with platelet-rich plasma or other platelet-containing substance either by hand, in a device, or by applying the MPH directly to the wound before or after application of the platelet-containing substance. Alternatively, MPH can by applied directly to the bleeding wound, using the blood as a source of platelets.